PREVYMIS (letermovir), Merck
Indications: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Dosage: 480 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-transplant. If PREVYMIS is coadministered with cyclosporine, the dosage of PREVYMIS should be decreased to 240 mg once daily.
Contraindications: Pimozide, Ergot alkaloids, and pitavastatin and simvastatin when co-administered with cyclosporine.